C. Escuriola-Ettingshausen

发表

Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel

C. Königs, J. Oldenburg, G. Auerswald, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

J. Oldenburg, R. Ljung, E. Santagostino, 2017, Thrombosis and Haemostasis.

Intensity of factor VIII treatment and the development of inhibitors in non‐severe hemophilia A patients: results of the INSIGHT case–control study

S. Cessie, J. Astermark, R. Keenan, 2017, Journal of thrombosis and haemostasis : JTH.

nonsevere hemophilia A ) mutation and risk of inhibitor development in F8 Factor VIII gene (

J. Astermark, R. Keenan, J. Oldenburg, 2014 .

GENERAL INTRODUCTION AND OUTLINE OF THE THESIS

J. Astermark, R. Keenan, J. Oldenburg, 2012 .

THROMBOSIS AND HEMOSTASIS Factor VIII gene ( F 8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

J. Astermark, R. Keenan, J. Oldenburg, 2013 .

Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A

C. Königs, J. Oldenburg, C. Escuriola-Ettingshausen, 2020, Hämostaseologie.

Factor VIII Inhibitors in Patients with Hemophilia A: Epidemiology of Inhibitor Development and Induction of Immune Tolerance for Factor VIII

G. Auerswald, C. Escuriola-Ettingshausen, G. Auerswald, 1995, Seminars in thrombosis and hemostasis.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

J. Oldenburg, E. Santagostino, M. Carcao, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

The application of bypassing‐agent prophylaxis in haemophilia A patients with inhibitors: a meeting report

L. Valentino, C. Leissinger, V. Blanchette, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Epidemiology of Inhibitor Development in Haemophilia A Patients Treated with Virus– Inactivated Plasma–Derived Clotting Factor Concentrates

C. Escuriola-Ettingshausen, W. Kreuz, B. Kornhuber, 1999, Vox Sanguinis.

Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors

C. Escuriola-Ettingshausen, N. Ewing, W. Kreuz, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

When should prophylactic treatment in patients with haemophilia A and B start?— The German experience

C. Kessler, C. Escuriola-Ettingshausen, W. Kreuz, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis

C. Escuriola-Ettingshausen, W. Kreuz, M. Funk, 1998, Annals of Hematology.

Immune tolerance induction: What have we learned over time?

C. Escuriola-Ettingshausen, E. Berntorp, H. Brackmann, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Epidemiology of Inhibitors in Haemophilia A

C. Escuriola-Ettingshausen, W. Kreuz, B. Kornhuber, 1996, Vox sanguinis.

Prophylaxis re‐visited: The potential impact of novel factor and non‐factor therapies on prophylaxis

C. Leissinger, T. Lambert, E. Santagostino, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A

C. Escuriola-Ettingshausen, K. Kurnik, R. Klamroth, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Epitope Mapping during FVIII Inhibitor Elimination with Rituximab Reveals Conformational Epitopes on FVIII and Identifies Small Molecules Blocking Inhibitor and Targeting B Cells

U. Dietrich, C. Königs, T. Klingebiel, 2006 .

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021

C. Escuriola-Ettingshausen, Y. Dargaud, 2021, Research and practice in thrombosis and haemostasis.

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

C. Leissinger, T. Lambert, E. Santagostino, 2015 .

Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study

J. Oldenburg, C. Escuriola-Ettingshausen, K. Kurnik, 2021, Blood.

A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany – First Data from the GEPHARD Study Group

C. Königs, W. Behnisch, J. Oldenburg, 2021, Hämostaseologie.

Erratum: A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany – First Data from the GEPHARD Study Group

C. Königs, W. Behnisch, J. Oldenburg, 2021, Hämostaseologie.

Protein-C concentrate for meningococcal purpura fulminans

C. Escuriola-Ettingshausen, W. Kreuz, A. Veldman, 1998, The Lancet.

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate® in the Observational ObsITI Study,

C. Escuriola-Ettingshausen, V. Vdovin, N. Zozulya, 2011 .

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study

O. Stasyshyn, C. Escuriola-Ettingshausen, J. Windyga, 2023, Therapeutic Advances in Hematology.

EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis

P. Fontana, C. Escuriola-Ettingshausen, M. Albisetti, 2023, GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark.

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

J. Astermark, R. Keenan, V. Jiménez‐Yuste, 2013, Blood.